Suppr超能文献

评估丙酮酸激酶缺乏症中系统性铁稳态的主要调节剂。

Evaluation of the main regulators of systemic iron homeostasis in pyruvate kinase deficiency.

机构信息

Hematology Unit, Pathophysiology of Anemias Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Department of Molecular Medicine and Medical Biotechnology, University Federico II, Naples, Italy.

出版信息

Sci Rep. 2023 Mar 16;13(1):4395. doi: 10.1038/s41598-023-31571-2.

Abstract

Iron homeostasis and dyserythropoiesis are poorly investigated in pyruvate kinase deficiency (PKD), the most common glycolytic defect of erythrocytes. Herein, we studied the main regulators of iron balance and erythropoiesis, as soluble transferrin receptor (sTfR), hepcidin, erythroferrone (ERFE), and erythropoietin (EPO), in a cohort of 41 PKD patients, compared with 42 affected by congenital dyserythropoietic anemia type II (CDAII) and 50 with hereditary spherocytosis (HS). PKD patients showed intermediate values of hepcidin and ERFE between CDAII and HS, and clear negative correlations between log-transformed hepcidin and log-EPO (Person's r correlation coefficient =  - 0.34), log-hepcidin and log-ERFE (r =  - 0.47), and log-hepcidin and sTfR (r =  - 0.44). sTfR was significantly higher in PKD; EPO levels were similar in PKD and CDAII, both higher than in HS. Finally, genotype-phenotype correlation in PKD showed that more severe patients, carrying non-missense/non-missense genotypes, had lower hepcidin and increased ERFE, EPO, and sTFR compared with the others (missense/missense and missense/non-missense), suggesting a higher rate of ineffective erythropoiesis. We herein investigated the main regulators of systemic iron homeostasis in the largest cohort of PKD patients described so far, opening new perspectives on the molecular basis and therapeutic approaches of this disease.

摘要

铁稳态和红细胞生成不良在丙酮酸激酶缺乏症(PKD)中研究甚少,PKD 是红细胞最常见的糖酵解缺陷。在此,我们研究了铁平衡和红细胞生成的主要调节剂,包括可溶性转铁蛋白受体(sTfR)、hepcidin、erythroferrone(ERFE)和促红细胞生成素(EPO),在 41 名 PKD 患者的队列中,与 42 名患有先天性红细胞生成不良性贫血 II 型(CDAII)和 50 名遗传性球形红细胞增多症(HS)患者进行比较。PKD 患者的 hepcidin 和 ERFE 介于 CDAII 和 HS 之间,hepcidin 和 log-EPO(Person's r 相关系数= -0.34)、hepcidin 和 log-ERFE(r= -0.47)、hepcidin 和 sTfR(r= -0.44)之间存在明显的负相关。sTfR 在 PKD 中显著升高;PKD 和 CDAII 中的 EPO 水平相似,均高于 HS。最后,PKD 的基因型-表型相关性显示,携带非错义/非错义基因型的更严重患者的 hepcidin 水平较低,而 ERFE、EPO 和 sTFR 水平较高,与其他患者(错义/错义和错义/非错义)相比,提示无效红细胞生成率较高。我们在此研究了迄今为止描述的最大 PKD 患者队列中系统铁稳态的主要调节剂,为该疾病的分子基础和治疗方法开辟了新的视角。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/324b/10020532/e88ccfa30cc2/41598_2023_31571_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验